FDA, PTO, Novartis, Alexion, and BioNTech to Present at ACI's Novel Therapeutics

NEW YORK - Feb. 13, 2023 - PRLog -- American Conference Institute (ACI) is pleased to announce that representatives from the U.S. Food and Drug Administration (FDA) and the United States Patent and Trademark Office (USPTO) are confirmed to speak at ACI's The National Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities and Gene Therapies, taking place March 21-22, 2023, at the Omni Parker House Boston.

mRNA, CRISPR, CAR T – all acronyms for emerging and novel therapeutics that are changing modern medicine as we know it. However, the complexities concerning ownership, funding and tech strategies for these next-generation therapeutic modalities and gene therapies are the greatest barriers to commercialization.

ACI has created this one-of-a-kind event to provide you with solutions to some of the greatest challenges impeding market access for these transformative products.

Christine Bellon, 2023 Co-Chair and Chief Legal Officer at Beam Therapeutics, Inc. commented that, "I am looking forward to this meeting.  The science behind novel gene therapies is evolving at a rapid pace and this conference brings together leaders in business, law, and policy from the government, academia, and industry to talk about ways that the legal and regulatory regimes can adapt to keep pace with the science."

In addition, Sharick Naqi, 2023 Co-Chair and Director & Senior Counsel, Global IP Lead – Gene Therapies at Novartis Gene Therapies added, "We are excited to share the latest trends, challenges and strategic considerations for Novel Therapeutic Modalities and Gene Therapies, as well as take advantage of this unique opportunity to network with the larger community working on these ground-breaking treatments."

In response, Joseph Gallagher, Director of Content at ACI, remarked, "We are proud to host this revolutionary event that will gather representatives from the USPTO and FDA, as well as, distinguished in-house and outside counsel to discuss IP and regulatory initiatives that are essential to the proliferation of these therapeutics."  Gallagher added, "We look forward to bringing this year's event to Boston, the biopharma industry's new mecca, and are honored to work with this stellar group of distinguished speaking faculty."

Lisa J. Piccolo, Associate VP with ACI, noted, "we are honored to have Julia Tierney (FDA), Kendalle Burlin O'Connell, Esq. (MassBio), Christine Bellon (Beam Therapeutics, Inc) and Sharick Naqi (Novartis Gene Therapies), participate in this year's conference. Their presence at the event is a testament to the "must-attend" status of this conference."

Full information on the event, visit https://www.americanconference.com/novel-therapies/

# # #

A unique organization, American Conference Institute is devoted to providing the business intelligence that senior decision-makers need to respond to challenges both here in the US, and around the world.